- Home » News and Events

NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent and Bhami Research Laboratory Enter into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously
Mar 16, 2023
Under the terms of the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.
Catalent Expands UpTempo℠ AAV Platform to Accelerate Development of Gene Therapies
Mar 9, 2023
Catalent today announced the expansion of its UpTempo℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.
Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium
Jan 26, 2023
The state-of-the-art facility contains development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply
Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies
Jan 24, 2023
The new Case Management Service addresses challenges associated with delivering advanced therapies to patients by providing supply chain oversight from program start to finish.
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
Jan 17, 2023
Mr. Zayas will be responsible for Catalent’s North American biologics operations. He will serve on the Executive Leadership Team, reporting directly to President & CEO, Alessandro Maselli.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Jan 5, 2023
Catalent and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.
Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina
Dec 14, 2022
The new facility within North Carolina’s Research Triangle, will offer comprehensive analytical development and testing for biologic drug modalities.
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Gosselies, Belgium
Dec 8, 2022
The new facility will be one of the largest in the world with multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Nov 3, 2022
The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology.
Overcoming Formulation Challenges for mRNA and High-Concentration Proteins
Date: March 30, 2023
World Vaccine Congress Washington 2023
Date: April 3-6, 2023
Cell & Gene Meeting on the Med 2023
Date: April 12-14, 2023
2023 PDA Visual Inspection Forum
Date: April 17-18, 2023
CASSS Bioassays 2023
Date: April 17-19, 2023
2nd LNP Formulation & Process Development Summit
Date: April 17-19, 2023
Process Optimization for Monoclonal Antibody (mAb) Commercial Manufacturing
Date: April 25, 2023
INTERPHEX 2023
Date: April 25-27, 2023
Exploring a One-Stop Integrated Solution for AAV Vector Clinical Production
Date: May 3, 2023
PEGS Boston 2023
Date: May 15-19, 2023
ASGCT 26th Annual Meeting
Date: May 16-20, 2023
5th Annual Allogeneic Cell Therapies Summit
Date: May 22-25, 2023
ISCT 2023 Paris Annual Meeting
Date: May 31 – June 3, 2023
2023 BIO International Convention
Date: June 5-8, 2023
ISSCR 2023 Annual Meeting
Date: June 14-17, 2023